Physiologically based pharmacokinetic modelling of the co‐administration of ritonavir‐boosted atazanavir and rifampicin in children co‐treated for HIV and TB

Documenti analoghi

• Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis
  di: Megan Palmer, et al.
  Pubblicazione: (2025)
• Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis
  di: Sharon Sawe, et al.
  Pubblicazione: (2025)
• Pharmacokinetic data of lopinavir/ritonavir in second‐line treatment of African children living with HIV
  Pubblicazione: (2024)
• Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics
  di: Qiushi Wang, et al.
  Pubblicazione: (2024)
• Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy
  di: Maike Scherf‐Clavel, et al.
  Pubblicazione: (2025)